Zentaris (AEZS) Enterprise Value to EBITDA Ratio

Public company logo of Aeterna Zentaris Inc. (AEZS)

The historical price chart for Aeterna Zentaris (AEZS) demonstrates an EV/EBITDA ratio of . The business relies on patent protection for unique drugs, ensuring a monopoly in a niche segment following the completion of rigorous testing. Company growth is based on mergers with biotech startups and licensing alliances. Meanwhile, the market maintains cautious optimism, awaiting the results of new medical programs amid stable physician confidence.

Aeterna Zentaris Inc. - AEZS Company Value to EBITDA (period 07/04/2022 - 11/12/2026)

Comprehensive metric breakdowns and analytics for zentaris.com (AEZS)

- current price and projected stock value:
Stock Price Aeterna Zentaris Inc.|AEZS - Analyst Median Target
- market capitalization details:
Market Valuation AEZS|AEZS - Full Business Value
- business book valuation details:
Book Value per Share Aeterna Zentaris|AEZS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio zentaris.com|AEZS - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Aeterna Zentaris|AEZS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Aeterna Zentaris Inc.|AEZS - Company Aggregate Indebtedness|Debts to Book Capitalization AEZS|AEZS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Aeterna Zentaris|Quick Liquidity zentaris.com
- financial results and valuation multiples details:
AEZS - Final Profit|Expected Profit Aeterna Zentaris|AEZS - Price to Earnings Ratio|Forward P/E Multiple Aeterna Zentaris Inc.|AEZS - PEG Multiple|EV/EBITDA Multiple AEZS|AEZS - Operating profit EBITDA|Net earnings per share (EPS TTM) Aeterna Zentaris|AEZS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zentaris.com|AEZS - Net earnings per one share growth for the current year|Earnings growth forecast for next year Aeterna Zentaris
Fundamental valuation:Zentaris AEZS
Manufactured products of Aeterna Zentaris Inc.

The scaling of Aeterna Zentaris (AEZS) through M&A and the licensing of orphan drugs is directly reflected in the EV/EBITDA trend over the time interval. This multiple compares the total enterprise value with its operating profit before depreciation and amortization, determining the company's ability to service debt amid revenue volatility. Investors utilize this ratio to analyze the impact of cost inflation on the capitalization of distressed issuers.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|Chemomab - EV/EBITDA Multiple|SRXH - EV/EBITDA Multiple|PLRZ: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to EBITDA Ratio INZY|RPHM (reneopharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CSCI